What is the address of Dr. Céline Vanfraechem, Nefrologie?

The registered office of Dr. Céline Vanfraechem, Nefrologie is located at Vogelheide 6, 9052 Gent.

Is Dr. Céline Vanfraechem, Nefrologie still active?

Yes. According to the CBE (2 November 2026) Dr. Céline Vanfraechem, Nefrologie is active, legal situation “Normale toestand”, started on 12 October 2018.

Is Dr. Céline Vanfraechem, Nefrologie registered on Peppol?

Yes, Dr. Céline Vanfraechem, Nefrologie is registered on the Peppol network with ID 0208:0708969139.

What is the enterprise number of Dr. Céline Vanfraechem, Nefrologie?

The enterprise number of Dr. Céline Vanfraechem, Nefrologie is BE0708969139.

When was Dr. Céline Vanfraechem, Nefrologie founded?

Dr. Céline Vanfraechem, Nefrologie was founded on 12 October 2018.

Who are the directors of Dr. Céline Vanfraechem, Nefrologie?

According to the 2025 annual accounts, the directors of Dr. Céline Vanfraechem, Nefrologie are: Céline Vanfraechem.

Is Dr. Céline Vanfraechem, Nefrologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 October 2018; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Céline Vanfraechem, Nefrologie make in 2025?

Dr. Céline Vanfraechem, Nefrologie posted a profit after taxes of € 453,307 in financial year 2025.

What is the revenue of Dr. Céline Vanfraechem, Nefrologie?

As a small company, Dr. Céline Vanfraechem, Nefrologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 648,734.

Dr. Céline Vanfraechem, Nefrologie (Private Limited)

Dossier Dr. Céline Vanfraechem, Nefrologie, printed on 2 November 2026 from databakkes.be/en/0708969139/dr-celine-vanfraechem-nefrologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. Céline Vanfraechem, Nefrologie from Gent, company number BE0708969139, closed financial year 2025 with a result of € 453,307 after tax. For that financial year Dr. Céline Vanfraechem, Nefrologie recorded a gross margin of € 648,734 and equity of € 21,907. Compared with financial year 2024, the result moved from € 395,204 to € 453,307. Profitable, and profit is growing. The buffer shrank hard: equity is 95 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.

What it is worth Shrank hard

€ 21,907

▼ 95% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 453,307

▲ 15% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 429,184

▲ 37% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 845,204 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 193

▼ 99% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 757,000

▲ 175% vs 2024

Loans from banks and other lenders, long and short.

Taxes

€ 5,841

▼ 31% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 614,975 Gross margin 2022: € 614,975 First fiscal year in the series	€ 762,504 Gross margin 2023: € 762,504 ▲ 24% vs 2022 (€ 614,975) Favourable step	€ 571,803 Gross margin 2024: € 571,803 ▼ 25% vs 2023 (€ 762,504) Unfavourable step	€ 648,734 Gross margin 2025: € 648,734 ▲ 13% vs 2024 (€ 571,803) Favourable step	▲ 13%
Profit after taxes	€ 443,463 Profit after taxes 2022: € 443,463 First fiscal year in the series	€ 541,289 Profit after taxes 2023: € 541,289 ▲ 22% vs 2022 (€ 443,463) Favourable step	€ 395,204 Profit after taxes 2024: € 395,204 ▼ 27% vs 2023 (€ 541,289) Unfavourable step	€ 453,307 Profit after taxes 2025: € 453,307 ▲ 15% vs 2024 (€ 395,204) Favourable step	▲ 15%
Equity	€ 462,063 Equity 2022: € 462,063 First fiscal year in the series	€ 559,889 Equity 2023: € 559,889 ▲ 21% vs 2022 (€ 462,063) Favourable step	€ 413,804 Equity 2024: € 413,804 ▼ 26% vs 2023 (€ 559,889) Unfavourable step	€ 21,907 Equity 2025: € 21,907 ▼ 95% vs 2024 (€ 413,804) Unfavourable step	▼ 95%
Total debts	€ 326,909 Total debts 2022: € 326,909 First fiscal year in the series	€ 398,728 Total debts 2023: € 398,728 ▲ 22% vs 2022 (€ 326,909) Unfavourable step	€ 284,295 Total debts 2024: € 284,295 ▼ 29% vs 2023 (€ 398,728) Favourable step	€ 763,022 Total debts 2025: € 763,022 ▲ 168% vs 2024 (€ 284,295) Unfavourable step	▲ 168%
Cash	€ 392,945 Cash 2022: € 392,945 First fiscal year in the series	€ 567,115 Cash 2023: € 567,115 ▲ 44% vs 2022 (€ 392,945) Favourable step	€ 313,986 Cash 2024: € 313,986 ▼ 45% vs 2023 (€ 567,115) Unfavourable step	€ 429,184 Cash 2025: € 429,184 ▲ 37% vs 2024 (€ 313,986) Favourable step	▲ 37%
Retained profit	€ 443,463 Retained profit 2022: € 443,463 First fiscal year in the series	€ 541,289 Retained profit 2023: € 541,289 ▲ 22% vs 2022 (€ 443,463) Favourable step	€ 395,204 Retained profit 2024: € 395,204 ▼ 27% vs 2023 (€ 541,289) Unfavourable step	€ 3,307 Retained profit 2025: € 3,307 ▼ 99% vs 2024 (€ 395,204) Unfavourable step	▼ 99%
Dividend	€ 1,033,531 Dividend 2022: € 1,033,531 First fiscal year in the series	€ 443,463 Dividend 2023: € 443,463 ▼ 57% vs 2022 (€ 1,033,531) Unchanged	€ 541,289 Dividend 2024: € 541,289 ▲ 22% vs 2023 (€ 443,463) Unchanged	€ 845,204 Dividend 2025: € 845,204 ▲ 56% vs 2024 (€ 541,289) Unchanged	▲ 56%
Bank debt	€ 270,000 Bank debt 2022: € 270,000 First fiscal year in the series	€ 350,000 Bank debt 2023: € 350,000 ▲ 30% vs 2022 (€ 270,000) Unfavourable step	€ 275,020 Bank debt 2024: € 275,020 ▼ 21% vs 2023 (€ 350,000) Favourable step	€ 757,000 Bank debt 2025: € 757,000 ▲ 175% vs 2024 (€ 275,020) Unfavourable step	▲ 175%
Balance sheet total	€ 788,972 Balance sheet total 2022: € 788,972 First fiscal year in the series	€ 958,617 Balance sheet total 2023: € 958,617 ▲ 22% vs 2022 (€ 788,972) Unchanged	€ 698,099 Balance sheet total 2024: € 698,099 ▼ 27% vs 2023 (€ 958,617) Unchanged	€ 784,929 Balance sheet total 2025: € 784,929 ▲ 12% vs 2024 (€ 698,099) Unchanged	▲ 12%

Key figures of Dr. Céline Vanfraechem, Nefrologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Céline Vanfraechem, Nefrologie?

What happened at Dr. Céline Vanfraechem, Nefrologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 30, 2026 New annual accounts for financial year 2025: profit of € 453,307 (▲ 15% vs 2024). Source: NBB ↗
Oct 12, 2018 New establishment in Gent. KBO
Oct 12, 2018 Start of the company according to the CBE. KBO

In short

From € 443,463 profit in 2022 to € 453,307 profit in 2025.

Paid € 606,181 in corporate taxes since 2022.

Best year ever: 2023, with € 541,289 profit.

Paid out € 2.9 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Céline Vanfraechem

Dr. Céline Vanfraechem, Nefrologie

Behind Dr. Céline Vanfraechem, Nefrologie is Céline Vanfraechem.

Directors

According to the 2025 annual accounts

Céline Vanfraechem

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Vogelheide 6

9052 Gent

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0708.969.139
VAT number: BE 0708.969.139
Registered office: Vogelheide 6, 9052 Gent
Names & denominations: Dr. Céline Vanfraechem, Nefrologie
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 12 October 2018
Peppol: Active · Active since 5 Jan 2026

View on CBE Public ↗ Annual accounts (NBB) ↗